Savior Lifetec Cash Flow Conversion Efficiency

Latest as of December 2025: -0.026x

Savior Lifetec cash flow conversion efficiency. Based on the latest financial reports, Savior Lifetec (4167) has a cash flow conversion efficiency ratio of -0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-98.65 Million ≈ $-3.11 Million USD) by net assets (NT$3.78 Billion ≈ $119.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Savior Lifetec (2011–2025)

Cash flow conversion efficiency of Savior Lifetec from 2011 to 2025. This chart illustrates how Savior Lifetec's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Savior Lifetec stock price for real-time trading data and today's change.

Savior Lifetec Cash Flow Conversion Ratio Explained

Savior Lifetec cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Savior Lifetec Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Savior Lifetec ranked by their cash flow conversion efficiency. Also see 4167 market cap overview for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Action S.A.
WAR:ACT
0.059x
Aofu Environmental Technology Co Ltd
SHG:688021
0.022x
HLB Pharmaceutical Co. Ltd
KQ:047920
0.015x
Amcil Ltd
AU:AMH
0.008x
Young Fast Optoelectronics Co Ltd
TW:3622
0.016x
Akwel SA
PA:AKW
0.048x
OBI Pharma
TWO:4174
-0.132x
Winton Land Ltd
AU:WTN
-0.019x

Annual Cash Flow Conversion Efficiency for Savior Lifetec (2011–2025)

The table below shows the annual cash flow conversion efficiency of Savior Lifetec from 2011 to 2025. Review 4167 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 NT$3.78 Billion
≈ $119.12 Million
NT$-21.04 Million
≈ $-662.91K
-0.006x -103.77%
2024-12-31 NT$3.52 Billion
≈ $110.78 Million
NT$518.38 Million
≈ $16.33 Million
0.147x +27.87%
2023-12-31 NT$3.36 Billion
≈ $106.01 Million
NT$387.95 Million
≈ $12.22 Million
0.115x -33.27%
2022-12-31 NT$3.37 Billion
≈ $106.08 Million
NT$581.77 Million
≈ $18.33 Million
0.173x +440.04%
2021-12-31 NT$3.31 Billion
≈ $104.37 Million
NT$-168.34 Million
≈ $-5.30 Million
-0.051x -285.45%
2020-12-31 NT$3.33 Billion
≈ $104.92 Million
NT$91.25 Million
≈ $2.87 Million
0.027x -61.21%
2019-12-31 NT$2.21 Billion
≈ $69.75 Million
NT$156.40 Million
≈ $4.93 Million
0.071x +169.06%
2018-12-31 NT$1.86 Billion
≈ $58.47 Million
NT$-189.84 Million
≈ $-5.98 Million
-0.102x -184.82%
2017-12-31 NT$2.16 Billion
≈ $68.15 Million
NT$260.89 Million
≈ $8.22 Million
0.121x +435.93%
2016-12-31 NT$2.12 Billion
≈ $66.77 Million
NT$-76.09 Million
≈ $-2.40 Million
-0.036x +86.25%
2015-12-31 NT$1.59 Billion
≈ $50.15 Million
NT$-415.82 Million
≈ $-13.10 Million
-0.261x -265.61%
2014-12-31 NT$1.29 Billion
≈ $40.75 Million
NT$-92.41 Million
≈ $-2.91 Million
-0.071x -16.66%
2013-12-31 NT$1.39 Billion
≈ $43.93 Million
NT$-85.39 Million
≈ $-2.69 Million
-0.061x +65.70%
2012-12-31 NT$1.27 Billion
≈ $40.16 Million
NT$-227.59 Million
≈ $-7.17 Million
-0.179x +48.89%
2011-12-31 NT$1.31 Billion
≈ $41.38 Million
NT$-458.82 Million
≈ $-14.46 Million
-0.349x --

About Savior Lifetec

TWO:4167 Taiwan Biotechnology
Market Cap
$191.21 Million
NT$6.07 Billion TWD
Market Cap Rank
#16527 Global
#797 in Taiwan
Share Price
NT$19.55
Change (1 day)
+0.26%
52-Week Range
NT$16.70 - NT$22.40
All Time High
NT$40.63
About

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more